Información del artículo
Los pacientes con lupus eritematoso sistémico (LES) padecen una serie de afecciones asociadas con mayor incidencia que en la población general. Esta comorbilidad incluye: infecciones, arteriosclerosis, arteriopatía coronaria, osteoporosis y necrosis avascular ósea, entre las más frecuentes. En general, estas complicaciones se relacionan, sobre todo, con el grado de actividad del LES y con las dosis de corticoides diarias y acumuladas. Se trata de resaltar la importancia que tiene esta comorbilidad para el pronóstico de nuestros pacientes y que debe estar presente a la hora de establecer el tratamiento en cada una de sus visitas.
Palabras clave:
Lupus
Comorbilidad
Infección
Arteriosclerosis
Osteoporosis
Patients with systemic lupus erythematosus (SLE) suffer a series of incidence-associated pathologies more frequent than general population. Comorbility includes: infections, arteriosclerosis, coronary arteriopathy, osteoporosis, and avascular necrosis of the bone, to name the more frequent ones. In general, such complications are related, above all, to the degree of SLE activity and the dosages of daily and accumulated corticoids. It is a matter of highlighting the importance of the associated pathologies in regards to our patients’ prognosis and of taking them into consideration when we establish a treatment for our patients’ during each one of their visits.
Key words:
Lupus
Comorbility
Infection
Arteriosclerosis
Osteoporosis
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.D. Gladman, M.B. Urowitz.
Morbidity in systemic lupus erythematosus.
J Rheumatol, 14 (1987), pp. 223-226
[2.]
M. Petri, S. Perez-Gutthann, J.C. Longenecker, M.C. Hochberg.
Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status.
Ann J Med, 91 (1991), pp. 345-353
[3.]
M. Petri, M. Genovese.
Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort.
J Rheumatol, 19 (1992), pp. 1559-1565
[4.]
F. Formiga Pérez, I. Moga Sampere, R. Canet González, M. Pac Ferraz, F. Mitjavila Villero, F. Fernández Nogués.
Infection and systemic lupus erythematosus: analisis of a series of 145 patients.
Rev Clin Esp, 193 (1993), pp. 105-109
[5.]
F.J. Blanco, J.J. Gómez-Reino, J. De La Maza, A. Corrales, V. Rodriguez-Valverde, J.C. Rosas, et al.
Survival analysis of 306 European Spanish patients with systemic lupus erythematosus.
Lupus, 7 (1998), pp. 159-163
[6.]
R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, P. Lavilla, A.O. Aydintug, et al.
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1.000 patients. European Working Party on Systemic Lupus Erythematosus.
Medicine (Baltimore), 78 (1999), pp. 167-175
[7.]
S. Rosner, E.M. Ginzler, H.S. Diamond, M. Weiner, M. Schlesinger, J.F. Fries, et al.
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.
Arthritis Rheum, 25 (1982), pp. 612-617
[8.]
B. Holvast, A. Huckriede, C.G.M. Kallenberg, M. Bijl.
Influenza vaccination in systemic lupus erythematosus: Safe and protective?.
Autoimmun Rev, 6 (2007), pp. 300-305
[9.]
M.B. Urowitz, D. Ibáñez, D.D. Gladman.
Atherosclerotic vascular events in a single large lupus cohort: Prevalence and risk factors.
J Rheumatol, 34 (2007), pp. 70-75
[10.]
M.M. Ward.
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus.
Arthritis Rheum, 42 (1999), pp. 338-346
[11.]
S. Manzi, F. Selzer, K. Sutton-Tyrrell, S.G. Fitzgerald, J.E. Rairie, R.P. Tracy, et al.
Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.
Arthritis Rheum, 42 (1999), pp. 51-60
[12.]
K.H. Leona, E.T. Koh, P.H. Fena, M.L. Boey.
Lipid profiles in patients with systemic lupus erythematosus.
J Rheumatol, 21 (1994), pp. 1264-1267
[13.]
D.J. Wallace, A.L. Metzger, V.J. Stecher, B.A. Turnbull, P.A. Kern.
Colesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: Effects on lipid metabolism.
Am J Med, 89 (1990), pp. 322-326
[14.]
E.F. Borba, E. Bonfa.
Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy.
J Rheumatol, 28 (2001), pp. 780-785
[15.]
A. Abou-Raya, S. Abou-Raya.
Inflammation: A pivotal link between autoimmune diseases and atherosclerosis.
Autoimmun Rev, 5 (2006), pp. 331-337
[16.]
E. Krishnan.
Stroke subtypes among young patients with systemic lupus erythematosus.
Am J Med, 118 (2005), pp. e1-7
[17.]
Y. Molad, N. Levin-Laina, M. Vaturi, J. Sulkes, A. Sagie.
Herth valve calcification in young patients with systemic lupus erythematosus: A window to premature atherosclerotic vascular morbidity and risk factor for all-cause mortality.
Atherosclerosis, 185 (2006), pp. 406-412
[18.]
B.F. Mandell.
Cardiovascular involvement in systemic lupus erythematosus.
Semin Arthritis Rheum, 17 (1987), pp. 126-141
[19.]
P.E. Lazzerini, P.L. Capecchi, F. Guideri, M. Acampa, M. Galeazzi, F. Laghi Pasini, et al.
Connective tissue diseases and cardiac rhythm disorders: An overview.
Autoimmun Rev, 5 (2006), pp. 306-313
[20.]
M. Abu-Shraka, M.B. Urowitz, D.D. Gladman, J. Gough.
Mortality studies in systemic lupus erythematosus. Results from a single centre. I. Causes of death.
J Rheumatol, 22 (1995), pp. 1259-1264
[21.]
D. Fen, R.W. Keen.
Osteoporosis in systemic lupus erythematosus: Prevalence and therapy.
Lupus, 10 (2001), pp. 227-232
[22.]
Y. Kipen, R. Buchbinder, A. Forbes, B. Strauss, G. Littlejohn, E. Morand.
Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids.
J Rheumatol, 24 (2007), pp. 1922-1928
[23.]
F. Formiga, I. Moga, J.M. Nolla, M. Pac, F. Mitjavila, D. Roig-Escofet.
Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.
Ann Rheum Dis, 54 (1995), pp. 274-276
[24.]
R. Ramsey-Goldman, S. Mamzi.
Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus.
Arthritis Rheum, 44 (2001), pp. 2338-2341
[25.]
S.C. Manalagas, R. Jilka.
Bone marrow, cytokines and bone remodeling. Emerging insights into the patophysiology of osteoporosis.
N Engl J Med, 332 (1995), pp. 303-311
[26.]
E.E. Velayos, J.D. Leidholt, C.J. Smyth, R. Priest.
Arthropathy associated with steroid therapy.
Ann Intern Med, 64 (1966), pp. 759
[27.]
P.L. Williams, M. Corbett.
Avascular necrosis of bone complicating corticosteroid replacement therapy.
Ann Rheum Dis, 42 (1983), pp. 276-279
[28.]
M. Petri.
Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update.
Arthritis Care Res, 8 (1995), pp. 137-145
[29.]
E.L. Dubois, L. Cozen.
Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus.
JAMA, 174 (1960), pp. 108
[30.]
J.S. Sheik, G.S. Retzinger, H.V. Hess.
Association of osteonecrosis in systemic lupus erythematosus with anormalities of fibrinolysis.
Lupus, 7 (1998), pp. 42-48
[31.]
M.A. Mont, C.J. Glueck, I.H. Pacheco, P. Wang, D.S. Hungerford, M. Petri.
Risk factors for osteonecrosis in systemic lupus erythematosus.
J Rheumatol, 24 (1997), pp. 654-662
[32.]
D.A. Blueinke, M. Petri, E.A. Zerhouni.
Femoral head perfusion and composition: MR imaging and spectroscopic evaluation of patients with systemic lupus erythematosus and at risk for avascular necrosis.
Radiology, 197 (1995), pp. 433-438
[33.]
G.S. Cooper, M.A. Dooley, E.L. Treadwell, E.W. St Clair, G.S. Gil Keson.
Hormonal and reproductive risk factors for development of systemic lupus erythematosus: Results of a population-based, case-control study.
Arthritis Rheum, 46 (2002), pp. 1830-1839
[34.]
A. Zonana-Nacach, S. Barr, L. Magder, M. Petri.
Damage in SLE and its association with prednisone [resumen].
Arthritis Rheum, 41 (1998), pp. S218
[35.]
S. Bernatsky, J. Boivin, J. Rajan, A. Zoma, S. Manzi, E. Ginzler, et al.
An international cohort study of cancer in systemic lupus erythematosus.
Arthritis Rheum, 52 (2005), pp. 1481-1490
[36.]
J. Bin, S. Bernatsky, C. Gordon, J. Boivin, E. Ginzler, D. Gladman, et al.
Lung cancer in systemic lupus erythematosus.
Lung Cancer, 56 (2007), pp. 303-306
[37.]
L. Bjornadal, B. Lofstrom, L. Yin, I. Lundberg, A. Ekbom.
Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus.
Scand J Rheumatol, 31 (2002), pp. 66-71
[38.]
J. Cibere, J. Sibley, M. Haga.
Systemic lupus erythematosus and the risk of malignancy.
Lupus, 10 (2001), pp. 394-400
[39.]
J.F. Sequeiro, D. Cesic, G. Keser, M. Bukelica, S. Karanagnostis, M.A. Khamashtam, et al.
Allergic disorders in systemic lupus erythematosus.
Allergol Immunol (Madr), 13 (1985), pp. 323-326
[40.]
S. Gaucha, S. Hamzaoui, M. Abdallam, K. Bouslama, A. Harmel, M. Ennafaa, et al.
Association lupus érythémateux systémique et psoriasis. À propos d’une observation.
J Rev Med, 26 (2005), pp. 431-433
[41.]
F. Wolfe, H.A. Smythe, M.B. Yunus, R.M. Bennet, C. Bombardier, D.L. Goldenberg.
The American College of Rheumatology 1990 criteria for the classification of fibromialgia: Report of the Multicentre Criteria Committee.
Arthritis Rheum, 33 (1990), pp. 160-172
[42.]
D.D. Gladman, M.B. Urowitz.
Morbidity in systemic lupus erythematosus.
J Rheumatol, 14 (1987), pp. 223-226
[43.]
S. Manzi, E.N. Meilahn, J.E. Rairie, C. Conte, T.A. Medsger, L. Jansen-McWilliams, et al.
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study.
Am J Epidemiol, 145 (1997), pp. 408-415
[44.]
M. Petri, S. Pérez-Gutthann, D. Spence, M.C. Hochberg.
Risk factors for coronary artery disease in patients with systemic lupus erythematosus.
Am J Med, 93 (1992), pp. 513-519
[45.]
R. Cervera, on behalf of the members of the European Working Party on Systemic Lupus Erythematosus Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the “Euro-Lupus Proyect”.
Autoimm Rev, 5 (2006), pp. 180-186
[46.]
S. Bernatsky, J.F. Boivin, L. Joseph, S. Manzi, E. Ginzler, D.D. Gladman, et al.
Mortality in systemic lupus erythematosus.
Arthritis Rheum, 54 (2006), pp. 2550-2557
Copyright © 2008. Elsevier España S.L. Barcelona
